Increased haemoglobin A2 percentage in HIV infection: Disease or treatment?

AIDS

Volumn 21, Issue 9, 2007, Pages 1207-1208

  Wilkinson, Michelle J ^a   Bain, Barbara J ^a   Phelan, Lorraine ^a   Benzie, Andrew ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN A2; ZIDOVUDINE;

ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; HEMOGLOBIN A2; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 34248585043     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32810c8d16     Document Type: Article

References (2)

1. 2 in human immunodeficiency virus-1-infected patients treated with zidovudine. Am J Hematol 1993; 43:86-90.
2. 2 levels in HIV-positive women in the antenatal clinic. J Clin Pathol 2005; 58:556-558.